138 related articles for article (PubMed ID: 10533477)
1. Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial.
van Driel WJ; Ressing ME; Kenter GG; Brandt RM; Krul EJ; van Rossum AB; Schuuring E; Offringa R; Bauknecht T; Tamm-Hermelink A; van Dam PA; Fleuren GJ; Kast WM; Melief CJ; Trimbos JB
Eur J Cancer; 1999 Jun; 35(6):946-52. PubMed ID: 10533477
[TBL] [Abstract][Full Text] [Related]
2. Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.
Ressing ME; van Driel WJ; Brandt RM; Kenter GG; de Jong JH; Bauknecht T; Fleuren GJ; Hoogerhout P; Offringa R; Sette A; Celis E; Grey H; Trimbos BJ; Kast WM; Melief CJ
J Immunother; 2000; 23(2):255-66. PubMed ID: 10746552
[TBL] [Abstract][Full Text] [Related]
3. Induction of tumor-specific CD4+ and CD8+ T-cell immunity in cervical cancer patients by a human papillomavirus type 16 E6 and E7 long peptides vaccine.
Welters MJ; Kenter GG; Piersma SJ; Vloon AP; Löwik MJ; Berends-van der Meer DM; Drijfhout JW; Valentijn AR; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; Melief CJ; van der Burg SH
Clin Cancer Res; 2008 Jan; 14(1):178-87. PubMed ID: 18172269
[TBL] [Abstract][Full Text] [Related]
4. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.
Kenter GG; Welters MJ; Valentijn AR; Lowik MJ; Berends-van der Meer DM; Vloon AP; Drijfhout JW; Wafelman AR; Oostendorp J; Fleuren GJ; Offringa R; van der Burg SH; Melief CJ
Clin Cancer Res; 2008 Jan; 14(1):169-77. PubMed ID: 18172268
[TBL] [Abstract][Full Text] [Related]
5. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.
van Poelgeest MI; Welters MJ; van Esch EM; Stynenbosch LF; Kerpershoek G; van Persijn van Meerten EL; van den Hende M; Löwik MJ; Berends-van der Meer DM; Fathers LM; Valentijn AR; Oostendorp J; Fleuren GJ; Melief CJ; Kenter GG; van der Burg SH
J Transl Med; 2013 Apr; 11():88. PubMed ID: 23557172
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy of a human papillomavirus (HPV) type 16 E7-expressing tumour by administration of fusion protein comprising Mycobacterium bovis bacille Calmette-Guérin (BCG) hsp65 and HPV16 E7.
Chu NR; Wu HB; Wu T; Boux LJ; Siegel MI; Mizzen LA
Clin Exp Immunol; 2000 Aug; 121(2):216-25. PubMed ID: 10931134
[TBL] [Abstract][Full Text] [Related]
7. HPV16/18 E7-pulsed dendritic cell vaccination in cervical cancer patients with recurrent disease refractory to standard treatment modalities.
Santin AD; Bellone S; Palmieri M; Ravaggi A; Romani C; Tassi R; Roman JJ; Burnett A; Pecorelli S; Cannon MJ
Gynecol Oncol; 2006 Mar; 100(3):469-78. PubMed ID: 16249018
[TBL] [Abstract][Full Text] [Related]
8. Natural T-helper immunity against human papillomavirus type 16 (HPV16) E7-derived peptide epitopes in patients with HPV16-positive cervical lesions: identification of 3 human leukocyte antigen class II-restricted epitopes.
van der Burg SH; Ressing ME; Kwappenberg KM; de Jong A; Straathof K; de Jong J; Geluk A; van Meijgaarden KE; Franken KL; Ottenhoff TH; Fleuren GJ; Kenter G; Melief CJ; Offringa R
Int J Cancer; 2001 Mar; 91(5):612-8. PubMed ID: 11267969
[TBL] [Abstract][Full Text] [Related]
9. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides.
Ressing ME; Sette A; Brandt RM; Ruppert J; Wentworth PA; Hartman M; Oseroff C; Grey HM; Melief CJ; Kast WM
J Immunol; 1995 Jun; 154(11):5934-43. PubMed ID: 7538538
[TBL] [Abstract][Full Text] [Related]
10. Vaccination against Oncoproteins of HPV16 for Noninvasive Vulvar/Vaginal Lesions: Lesion Clearance Is Related to the Strength of the T-Cell Response.
van Poelgeest MI; Welters MJ; Vermeij R; Stynenbosch LF; Loof NM; Berends-van der Meer DM; Löwik MJ; Hamming IL; van Esch EM; Hellebrekers BW; van Beurden M; Schreuder HW; Kagie MJ; Trimbos JB; Fathers LM; Daemen T; Hollema H; Valentijn AR; Oostendorp J; Oude Elberink JH; Fleuren GJ; Bosse T; Kenter GG; Stijnen T; Nijman HW; Melief CJ; van der Burg SH
Clin Cancer Res; 2016 May; 22(10):2342-50. PubMed ID: 26813357
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.
Nonn M; Schinz M; Zumbach K; Pawlita M; Schneider A; Dürst M; Kaufmann AM
J Cancer Res Clin Oncol; 2003 Sep; 129(9):511-20. PubMed ID: 12905010
[TBL] [Abstract][Full Text] [Related]
12. Differential binding of viral peptides to HLA-A2 alleles. Implications for human papillomavirus type 16 E7 peptide-based vaccination against cervical carcinoma.
Ressing ME; de Jong JH; Brandt RM; Drijfhout JW; Benckhuijsen WE; Schreuder GM; Offringa R; Kast WM; Melief CJ
Eur J Immunol; 1999 Apr; 29(4):1292-303. PubMed ID: 10229097
[TBL] [Abstract][Full Text] [Related]
13. Pre-immature dendritic cells (PIDC) pulsed with HPV16 E6 or E7 peptide are capable of eliciting specific immune response in patients with advanced cervical cancer.
Rahma OE; Herrin VE; Ibrahim RA; Toubaji A; Bernstein S; Dakheel O; Steinberg SM; Abu Eid R; Mkrtichyan M; Berzofsky JA; Khleif SN
J Transl Med; 2014 Dec; 12():353. PubMed ID: 25510844
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic uterine-cervix cancer vaccines in humans.
Gariglio P; Benitez-Bribiesca L; Berumen J; Alcocer JM; Tamez R; Madrid V
Arch Med Res; 1998; 29(4):279-84. PubMed ID: 9887543
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein.
Nilges K; Höhn H; Pilch H; Neukirch C; Freitag K; Talbot PJ; Maeurer MJ
J Virol; 2003 May; 77(9):5464-74. PubMed ID: 12692247
[TBL] [Abstract][Full Text] [Related]
16. T-helper epitopes identified within the E6 transforming protein of cervical cancer-associated human papillomavirus type 16.
Azoury-Ziadeh R; Herd K; Fernando GJ; Frazer IH; Tindle RW
Viral Immunol; 1999; 12(4):297-312. PubMed ID: 10630789
[TBL] [Abstract][Full Text] [Related]
17. Vaccination of full-length HPV16 E6 or E7 protein inhibits the growth of HPV16 associated tumors.
Li YL; Qiu XH; Shen C; Liu JN; Zhang J
Oncol Rep; 2010 Nov; 24(5):1323-9. PubMed ID: 20878127
[TBL] [Abstract][Full Text] [Related]
18. Antibodies against oncoproteins E6 and E7 of human papillomavirus types 16 and 18 in cervical-carcinoma patients from Russia.
Zumbach K; Kisseljov F; Sacharova O; Shaichaev G; Semjonova L; Pavlova L; Pawlita M
Int J Cancer; 2000 Feb; 85(3):313-8. PubMed ID: 10652419
[TBL] [Abstract][Full Text] [Related]
19. Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7.
Steller MA; Gurski KJ; Murakami M; Daniel RW; Shah KV; Celis E; Sette A; Trimble EL; Park RC; Marincola FM
Clin Cancer Res; 1998 Sep; 4(9):2103-9. PubMed ID: 9748126
[TBL] [Abstract][Full Text] [Related]
20. Cervical response to vaccination against HPV16 E7 in case of severe dysplasia.
Simon P; Buxant F; Hallez S; Burny A; Fayt I; Anaf V; Noël JC
Eur J Obstet Gynecol Reprod Biol; 2003 Aug; 109(2):219-23. PubMed ID: 12860346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]